Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
Rhea-AI Summary
Regeneron (NASDAQ: REGN) will report fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, released before U.S. markets open.
The company will host a conference call and simultaneous webcast on January 30, 2026 at 8:30 AM Eastern Time. Investors may join the live webcast via Regeneron’s Investors and Media web page or register in advance to participate by telephone and receive dial-in details, a unique passcode, and registrant ID.
A replay and transcript will be archived on the company website for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, REGN declined 1.68%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed, modest moves: ALNY +0.10%, ARGX +0.50%, VRTX +0.36%, while ONC -0.21% and INSM -0.08%. This contrasts with REGN’s slight -0.27% move, suggesting stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Drug approval Japan | Positive | +0.8% | Dupixent approval in Japan for children 6–11 with severe asthma. |
| Dec 22 | Conference presentation | Neutral | +0.8% | Announcement of presentation at 44th J.P. Morgan Healthcare Conference. |
| Dec 07 | Clinical data update | Positive | -2.1% | Positive Phase 1/2 Lynozyfic data in newly diagnosed multiple myeloma. |
| Dec 01 | New collaboration deal | Positive | -3.9% | TSRA-196 gene-editing collaboration for AATD with Tessera Therapeutics. |
| Nov 25 | Drug approval EU | Positive | +3.4% | EU approval of Dupixent for chronic spontaneous urticaria in patients 12+. |
Recent regulatory and clinical positives often saw aligned price gains, but there are notable divergences where strong clinical or partnership news coincided with share declines.
Over the last few months, Regeneron reported several key developments, including multiple approvals for Dupixent in the EU and Japan, positive early data for Lynozyfic (linvoseltamab), and a gene-editing collaboration on TSRA-196. Price reactions have been mixed: certain approvals produced gains up to 3.4%, while encouraging clinical data and a major collaboration coincided with declines of -2.1% and -3.86%. Against this backdrop, today’s simple scheduling of the January 30, 2026 earnings call is a routine milestone rather than a new fundamental shift.
Market Pulse Summary
This announcement sets the timetable for Regeneron’s fourth quarter and full-year 2025 results, with an earnings release and conference call on January 30, 2026. The stock was trading near its 52-week high at $771.87, above the 200-day MA of $603.78, and below-average volume of 351,711 shares. Recent history shows mixed price reactions to otherwise positive clinical and partnership news, so investors may watch upcoming earnings quality, product sales trends, and pipeline updates closely.
AI-generated analysis. Not financial advice.
TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
| Contact Information: | |
| Investor Relations | Corporate Communications |
| Ryan Crowe | Christina Chan |
| 914.847.8790 | 914.847.8827 |
| ryan.crowe@regeneron.com | christina.chan@regeneron.com |
FAQ
When will Regeneron (REGN) report Q4 and full year 2025 results?
What time is the Regeneron (REGN) earnings call and webcast on January 30, 2026?
How can investors access the Regeneron (REGN) January 30, 2026 webcast?
How do I join Regeneron’s (REGN) conference call by telephone for the January 30, 2026 results?
Will Regeneron (REGN) provide a replay or transcript of the January 30, 2026 call?
